Tyle M. Dylan-Hyde

Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA

Part of Cell-nique Corp., To Go Brands, Inc. develops and markets health products. The company is based in San Diego, CA. To Go Brands was acquired by Cell-nique Corp. from Taxus Cardium Pharmaceuticals Group, Inc. on November 18, 2013 for $2.50 million.

Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA.

Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA

Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA.

Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA.

Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA

Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA.

Tissue Repair Co. develops biopharmaceutical products for tissue regeneration. It is a biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is based on gene therapy, growth factor biology, tissue regeneration and product development. The company is headquartered in San Diego, CA

Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA.

Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA.

Post-Hypothermia Corp. develops and provides temperature modulation therapy products for the healthcare industry. It also provides CoolBlue, a surface-based temperature modulation system that consists of a console and a disposable CoolBlue vest with upper thigh pads, which is designed for use in less acute patients or prolonged temperature management clinical settings. The company was founded by John D. Dobak in 1998 and is headquartered in San Diego, CA.